



Note

In vitro inhibitory activity of sertraline against clinical isolates of *Sporothrix schenckii*

Hiram Villanueva-Lozano^a, Rogelio de J. Treviño-Rangel^a, Ricardo Téllez-Marroquín^b,
Alexandro Bonifaz^c, Olga C. Rojas^{a,d}, Pedro A. Hernández-Rodríguez^b, Gloria M. González^{a,*}

^a Department of Microbiology, School of Medicine, Universidad Autonoma de Nuevo Leon, Nuevo Leon, Mexico

^b Infectious Diseases Service, Department of Internal Medicine, University Hospital "Dr. José E. Gonzalez", Universidad Autonoma de Nuevo Leon, Nuevo Leon, Mexico

^c Dermatology Service & Mycology Department, Hospital General de Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico

^d Vice-rectory Health Sciences, Department of Basic Science, Universidad de Monterrey, Nuevo Leon, Mexico

ARTICLE INFO

Article history:

Received 10 July 2018

Accepted 4 January 2019

Available online 3 June 2019

Keywords:

Sporotrichosis

Synergy

Itraconazole

Voriconazole

Palabras clave:

Esporotricosis

Sinergia

Itraconazol

Voriconazol

ABSTRACT

Background: Sertraline (SRT) is an antidepressant that has proven its activity in vitro against *Cryptococcus*, *Coccidioides*, *Trichosporon* and other fungi. Disseminated sporotrichosis, although rare, has a high mortality and its treatment is difficult and prolonged, often relying in combining two or more antifungals.

Aims: In our study we evaluate the antifungal activity of SRT, alone and in combination with itraconazole (ITC), voriconazole (VRC) and amphotericin B (AMB), against 15 clinical isolates of *Sporothrix schenckii*.

Methods: We used the broth microdilution method as described by the CLSI to test the susceptibility to antifungals, and the checkerboard microdilution method to evaluate drug interactions.

Results: The minimum inhibitory concentration (MIC) with SRT was in the range of 4–8 µg/ml, while for AMB, VRC and ITC were 0.5–4 µg/ml, 0.5–8 µg/ml and 0.125–2 µg/ml, respectively. In addition, SRT showed synergy with ITC in one strain, mainly additivity with VRC, and indifference with AMB in others.

Conclusions: The MIC values with SRT for the isolates studied show the potential role of this drug as an adjuvant in the treatment of sporotrichosis, especially in disseminated or complicated cases.

© 2019 Asociación Española de Micología. Published by Elsevier España, S.L.U. All rights reserved.

Actividad inhibitoria in vitro de la sertralina frente a aislamientos clínicos de *Sporothrix schenckii*

RESUMEN

Antecedentes: La sertralina (SRT) es un antidepresivo que ha demostrado actividad in vitro contra *Cryptococcus*, *Coccidioides*, *Trichosporon* y otros hongos. La esporotricosis diseminada, aunque rara, tiene una mortalidad elevada y su tratamiento es complicado, requiriendo, a menudo, la combinación de dos o más antifúngicos.

Objetivos: En este estudio evaluamos la actividad antifúngica de SRT, sola y en combinación con itraconazol (ITC), voriconazol (VRC) y anfotericina B (AMB), frente a 15 aislamientos clínicos de *Sporothrix schenckii*.

Métodos: Se usó la técnica de microdilución en caldo para evaluar la sensibilidad a los antifúngicos y el método de tablero de damas para las interacciones entre estos fármacos.

Resultados: La concentración mínima inhibitoria (CMI) de SRT estuvo en el rango de 4–8 µg/ml, mientras que para AMB, VRC e ITC fue de 0,5–4 µg/ml, 0,5–8 µg/ml y 0,125–2 µg/ml, respectivamente. La SRT mostró sinergia con ITC frente a una cepa, efecto aditivo principalmente con VRC, e indiferencia con AMB.

* Corresponding author.

E-mail address: gmglez@yahoo.com.mx (G.M. González).

Conclusiones: Los valores de la CMI de SRT para los aislamientos ensayados son indicativos del potencial de este fármaco como adyuvante en el tratamiento de la esporotricosis, especialmente en casos complicados o de enfermedad diseminada.

© 2019 Asociación Española de Micología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Sporotrichosis is a deep subcutaneous mycotic infection caused by *Sporothrix schenckii* species complex that usually presents as localized cutaneous or subcutaneous disease. The drugs of choice include itraconazole, potassium iodide, amphotericin B and terbinafine, but their adverse effects, high price or restricted distribution represent a challenge.^{4,9,13,14}

Disseminated sporotrichosis has been associated with HIV/AIDS, uncontrolled diabetes and, in general, with impaired cellular immunity. Infection of the central nervous system (CNS) is one of the deadliest presentations of this disease. The usual treatment is based on the use of amphotericin B, but some studies have reported resistance. In HIV/AIDS-associated disease therapy varies when compared with immunocompetent patients, relying in the use of combination treatment, but mortality as high as 30% has been described.^{1–3,7,18,21} Sertraline (SRT) is an antidepressant with a worldwide distribution and an excellent tolerability profile. A certain antifungal activity has been recently found in this agent.^{8,20,23,24}

Combination therapy is a common standard in the management of multiple diseases, and the combination agents are chosen empirically. In this sense, synergy testing methods evaluate the combination of two or more drugs in comparison to its individual components.^{16,19} In this study we seek to study the activity of SRT against clinical isolates of *S. schenckii* and its combination with antifungals often used for the treatment of this infection.

Fifteen clinical isolates of *S. schenckii* collected from patients from the following states of Mexico, Puebla, Oaxaca, San Luis Potosi, Coahuila, Nuevo Leon, and Mexico City, were evaluated. Ten strains were isolated from male patients and five from females. One of them (16-021) belonged to a patient with disseminated sporotrichosis. These were previously identified by standard phenotypical

procedures and sequencing of the calmodulin gene fragment (sequences are available in GenBank, refer to Table 1 for accession numbers).¹⁵ Sequences were compared using NCBI-BLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>). The strains were stored as suspensions in sterile distilled water at room temperature, cultured for 7 days on Sabouraud-dextrose agar (SDA) at 30 °C, and then sub-cultured before use. Conidia were collected by scraping gently the surface of the plate and then suspended in sterile water. The turbidity of the supernatants was spectrophotometrically measured at 530 nm (UNICO Basic Visible Spectrophotometer 1100RS, Princeton, NJ, USA), and the transmittance was adjusted to 80–82%. Each suspension was diluted 1:50 in RPMI 1640 with L-glutamine and buffered with 165 mM MOPS (Hardy Diagnostics) to obtain two times the final inoculum size.

Voriconazole (VRC; Pfizer, Inc., New York, NY, USA), amphotericin B (AMB; Bristol-Myers Squibb, Princeton, NJ, USA), sertraline (SRT, TCI Chemicals Inc., New York, NY, USA) and itraconazole (ITC; Wako Pure Chemicals, Osaka, Japan) were obtained in reagent grade powder. Stock solutions of the drugs were made at 5 mg/ml in dimethyl sulfoxide and stored at –80 °C.

Antifungal susceptibility testing was conducted using the plate microdilution method according to document M38-A3 of the CLSI.⁵ The final drug concentrations ranged from 0.125 to 16 µg/ml for VRC, ITC and AMB, and from 0.5 to 32 µg/ml for SRT. *Candida parapsilosis* ATCC-22019 and *Paecilomyces variotii* MYA-3630 were used as quality control organisms. The checkerboard microdilution method was used to evaluate the activity of the combination of SRT and the antifungals (AMB, VRC and ITC). Drug interactions were defined in the basis of the fractional inhibitory concentration index (FICI): FIC A (MIC drug A in combination/MIC drug A alone) + FIC B (MIC drug B in combination/MIC drug B alone). Synergy was defined

Table 1
Antifungal susceptibility and synergistic effect of SRT against clinical isolates of *Sporothrix schenckii*.

Strain	GenBank accession number ^a	Lesion type ^b	Source of isolation	MIC ^c (µg/ml)				FICI ^d		
				SRT	AMB	VRC	ITC	SRT/AMB	SRT/VRC	SRT/ITC
12-078	MF948694	LC	Oaxaca	8	0.5	2	0.5	1.06	1.5	1.06
11-567	MF948693	LC	Nuevo Leon	4	0.5	2	2	1.125	0.625	1
00-45	MF948674	LC	Mexico city	8	1	8	0.5	1.06	1.015	0.75
16-09	MF948700	LC	Oaxaca	8	4	8	0.5	0.625	1.015	1.25
98-164	MF948670	LC	Mexico city	8	4	0.5	0.5	0.75	1	1
16-021	MF948702	D	Oaxaca	8	2	8	0.5	1.06	1.06	1
08-345	MF948688	LC	Coahuila	8	2	1	0.5	1.5	0.5625	1.25
06-345	MF948684	LC	SLP	8	2	4	0.5	1.5	1.5	1.25
11-131	MF948692	LC	Puebla	4	2	1	0.5	1.125	0.5625	1
16-022	MF948703	LC	Oaxaca	8	1	4	0.5	1.06	1.06	1.5
02-851	MF948680	LC	Mexico city	8	2	1	1	1.06	1	0.75
14-821	MF948696	LC	Puebla	8	1	4	0.125	1	0.625	0.625
08-390	MF948689	LC	Mexico city	8	2	2	2	1.06	0.53125	0.375
99-098	MF948672	LC	Mexico city	8	4	2	0.125	1.06	1.03	1.06
08-624	MF948690	LC	Nuevo Leon	4	0.5	0.5	0.5	1.125	0.75	1.125
ATCC 22019	NA	NA	Puerto Rico	8	0.5	<0.125	0.25	NA	NA	NA
MYA3630	NA	NA	USA	16	4	0.125	0.5	NA	NA	NA

^a GenBank accession numbers of CAL gene.

^b Lesion type: LC, lymphocutaneous; D, disseminated.

^c Minimum inhibitory concentration: SRT, sertraline; AMB, amphotericin B; VRC, voriconazole; ITC, itraconazole.

^d Fractional inhibitory concentration index.

as a FICI ≤ 0.5 , additivity as a FICI >0.5 and ≤ 1.0 , antagonism as a FICI >4.0 , and no interaction as a FICI >1.0 and ≤ 2.0 . The fractional inhibitory concentration (FIC) was determined as the concentration in the well that showed complete inhibition of growth compared visually with the controls; if more than one well showed similar inhibition, the well with the lowest FIC value was selected.^{17,19}

The MIC for SRT was in the range 4–8 $\mu\text{g/ml}$. The susceptibility of AMB ranged 0.5–4 $\mu\text{g/ml}$, 0.5–8 $\mu\text{g/ml}$ for VRC, and 0.125–2 $\mu\text{g/ml}$ for ITC. The combination of SRT and ITC showed a FICI value considered synergistic in one strain, and the other combinations presented additivity for many of the isolates assayed. None of the combinations tested presented antagonism (Table 1).

In our study, all isolates of *S. schenckii* exhibited MICs comparable to those previously reported for *Cryptococcus*, *Trichosporon* and *Coccidioides immitis*, and the antifungal activity was greater than that described for *Aspergillus* and *Candida*.^{6,10,11,22,24} In the combination study no antagonism was shown with the antifungal combinations tested; one strain exhibited synergism with ITC and an additive effect was observed in many other strains for different antifungal combinations. In other in vitro studies SRT showed a fungicidal activity proven by time-course assays of cell viability, and a higher potency in combination with azoles.²⁴ In our study, SRT alone showed an evident antifungal effect. Although we did not find any relevant combinatory activity in all the tested strains, synergy has been described in vivo even though it was not present in vitro. Moreover, SRT has the ability to reach 40–60 times its normal serum concentration in the CNS and the lung tissue.^{12,17,19} In conclusion, due to the potent antifungal activity SRT presented in this study, we can hypothesize that SRT could be a viable option as an adjuvant in the treatment of sporotrichosis, especially in the disseminated disease where lung and CNS involvement is common and the therapeutic approach is complicated. Further studies must be performed in order to determine the utility of this drug.

Funding sources

This work was supported by internal resources of the Department of Microbiology, School of Medicine, UANL.

Conflict of interest

The authors declare they have no conflict of interest.

Acknowledgments

Special thanks to Christian L. Campos Cortés, M.Sc. for her technical assistance.

References

- Bonifaz A, Tirado-Sánchez A. Cutaneous disseminated and extracutaneous sporotrichosis: current status of a complex disease. *J Fungi*. 2017;3:6.
- Bonifaz A, Tirado-Sánchez A, Paredes-Solis V, Cepeda-Valdés R, González GM, Treviño-Rangel R, et al. Cutaneous disseminated sporotrichosis: clinical experience of 24 cases. *J Eur Acad Dermatol Venereol*. 2018;32.
- Bunce PE, Yang L, Chun S, Zhang SX, Trinkaus MA, Matukas LM. Disseminated sporotrichosis in a patient with hairy cell leukemia treated with amphotericin B and posaconazole. *Sabouraudia*. 2012;50:197–201.
- Chakrabarti A, Bonifaz A, Gutierrez-Galhardo MC, Mochizuki T, Li S. Global epidemiology of sporotrichosis. *Med Mycol*. 2015;53:3–14.
- CLSI C. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard—second edition—document M38-A2; 2008.
- Cong L, Liao Y, Yang S, Yang R. In vitro antifungal activity of sertraline and synergistic effects in combination with antifungal drugs against planktonic forms and biofilms of clinical *Trichosporon asahii* isolates. *PLOS ONE*. 2016;11:e020167.
- de Lima Barros MB, de Almeida Paes R, Schubach AO. *Sporothrix schenckii* and sporotrichosis. *Clin Microbiol Rev*. 2011;24:633–54.
- Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. *Primary Care Companion J Clin Psychiatry*. 2001;3:22.
- Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2007;45:1255–65.
- Lass-Flörl C, Dierich M, Fuchs D, Semenitz E, Jenewein I, Ledochowski M. Antifungal properties of selective serotonin reuptake inhibitors against *Aspergillus* species in vitro. *J Antimicrob Chemother*. 2001;48:775–9.
- Lass-Flörl C, Ledochowski M, Fuchs D, Speth C, Kacani L, Dierich MP, et al. Interaction of sertraline with *Candida* species selectively attenuates fungal virulence in vitro. *FEMS Immunol Med Microbiol*. 2003;35:11–5.
- Lewis RJ, Angier MK, Williamson KS, Johnson RD. Analysis of sertraline in postmortem fluids and tissues in 11 aviation accident victims. *J Anal Toxicol*. 2013;37:208–16.
- Loyse A, Thangaraj H, Easterbrook P, Ford N, Roy M, Chiller T, et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. *Lancet Infect Dis*. 2013;13:629–37.
- Mahajan VK. Sporotrichosis: an overview and therapeutic options. *Dermatol Res Pract*. 2014;2014.
- Marimon R, Cano J, Gené J, Sutton DA, Kawasaki M, Guarro J. Three new *Sporothrix* species of clinical interest: *S. brasiliensis*, *S. globosa* and *S. mexicana*. *J Clin Microbiol*. 2007.
- McCarthy MW, Petraitis V, Walsh TJ. Combination therapy for the treatment of pulmonary mold infections. *Expert Rev Respir Med*. 2017;11:481–9.
- Meletiadiis J, Pournaras S, Roilides E, Walsh TJ. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations. Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against *Aspergillus fumigatus*. *Antimicrob Agents Chemother*. 2010;54:602–9.
- Moreira JA, Freitas DF, Lamas CC. The impact of sporotrichosis in HIV-infected patients: a systematic review. *Infection*. 2015;43:267–76.
- Odds FC. Synergy, antagonism, and what the checkerboard puts between them. *J Antimicrob Chemother*. 2003;52:1.
- Oliveira AS, Martinez-de-Oliveira J, Donders GG, Palmeira-de-Oliveira R, Palmeira-de-Oliveira A. Anti-*Candida* activity of antidepressants sertraline and fluoxetine: effect upon pre-formed biofilms. *Med Microbiol Immunol*. 2018;1–6.
- Paixão AG, Galhardo MCG, Almeida-Paes R, Nunes EP, Gonçalves MLC, Chequer GL, et al. The difficult management of disseminated *Sporothrix brasiliensis* in a patient with advanced AIDS. *AIDS Res Therapy*. 2015;12:16.
- Paul S, Mortimer RB, Mitchell M. Sertraline demonstrates fungicidal activity in vitro for *Coccidioides immitis*. *Mycology*. 2016;7:99–101.
- Rhein J, Morawski BM, Hullsiek KH, Nabeta HW, Kiggundu R, Tugume L, et al. Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. *Lancet Infect Dis*. 2016;16:809–18.
- Zhai B, Wu C, Wang L, Sachs MS, Lin X. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. *Antimicrob Agents Chemother*. 2012;56:3758–66.